TLDR
- Novavax (NVAX) stock jumped roughly 16% in trading on October 9.
- The move follows regulatory approvals in Belgium, Germany, and Portugal for Sanofi’s Phase 3 COVID-Influenza combination vaccine trial.
- Patient recruitment is set to begin in November, which would trigger a $125 million milestone payment from Sanofi to Novavax.
- The rally also reflects a cooldown after last week’s plague-scare driven swings.
- BofA raised its price target on Novavax to $8 from $7, though it kept an Underperform rating.
Novavax stock climbed about 16% on October 9. The move pushed the biotech back toward the upper end of its 52-week range.
The gain centers on fresh progress in Novavax’s partnership with Sanofi. Regulators in Belgium, Germany, and Portugal have approved Sanofi’s Phase 3 trial for a combined COVID-Influenza vaccine.
Patient recruitment for that trial is expected to start in November. That step would trigger a $125 million milestone payment from Sanofi to Novavax.
Why The Rally Is Different This Time
Last week told a different story. Novavax shares spiked more than 20% on Monday after a suspected plague case in Russia stirred pandemic-related buying.
Most of that move reversed on Tuesday. The World Health Organization said the public health risk was very low, and traders backed off.
Today’s move looks more grounded. There is no outbreak scare driving it, just a concrete regulatory step tied to a dated milestone payment.
The broader market helped too. The S&P 500 rose 0.3% and the Nasdaq Composite gained 0.3% on the day.
Other vaccine makers did not follow suit. Moderna and Pfizer showed no similar moves, suggesting this is a Novavax-specific story rather than a sector-wide shift.
The Royalty Math Behind The Stock
Novavax’s business model centers on royalties, not direct sales. The company collects royalties in the high-teens to low-20% range on Sanofi’s global Nuvaxovid net sales.
Beyond that, Novavax stands to collect up to $350 million in milestone payments tied to the combination vaccine. A separate $75 million payment is expected in mid-2027, linked to manufacturing technology transfer.
That structure means today’s rally is less about a single headline and more about investors re-pricing the path toward those future payments. The November recruitment start is the next concrete checkpoint.
Wall Street’s view on the stock remains mixed. The consensus analyst price target sits at $14, well above the current trading price.
Not every analyst is as upbeat. BofA’s Alec Stranahan raised his price target on Novavax to $8 from $7 on October 9, while maintaining an Underperform rating as part of a Q3 earnings preview for the biotech sector.
The new target still implies limited upside from current levels. It came alongside similar reviews across BofA’s biotech coverage list.
For now, the stock’s move is tied directly to the Sanofi trial timeline. The next milestone to watch is whether recruitment actually begins in November as planned.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
